Amalgamated Bank Sells 4,598 Shares of Illumina, Inc. (NASDAQ:ILMN)

Amalgamated Bank cut its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,924 shares of the life sciences company's stock after selling 4,598 shares during the quarter. Amalgamated Bank's holdings in Illumina were worth $9,901,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ILMN. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Illumina by 426.0% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company's stock valued at $2,123,000 after acquiring an additional 12,521 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new stake in shares of Illumina during the first quarter valued at about $4,527,000. US Bancorp DE grew its holdings in shares of Illumina by 33.9% during the first quarter. US Bancorp DE now owns 31,600 shares of the life sciences company's stock worth $4,339,000 after purchasing an additional 8,001 shares during the last quarter. Cetera Advisors LLC acquired a new position in shares of Illumina in the first quarter valued at approximately $610,000. Finally, Weybosset Research & Management LLC raised its holdings in Illumina by 92.0% in the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company's stock valued at $2,354,000 after buying an additional 8,650 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Down 2.0 %

ILMN stock traded down $3.13 during trading on Wednesday, reaching $151.83. The stock had a trading volume of 2,815,785 shares, compared to its average volume of 2,007,547. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $24.19 billion, a price-to-earnings ratio of -15.24 and a beta of 1.13. Illumina, Inc. has a one year low of $89.00 and a one year high of $156.66. The company's 50 day moving average is $137.27 and its two-hundred day moving average is $123.12.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. Illumina's quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.33 earnings per share. Equities research analysts forecast that Illumina, Inc. will post 3.62 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Daiwa Capital Markets raised shares of Illumina from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price target on the stock in a research report on Thursday, October 17th. Stephens reaffirmed an "overweight" rating and issued a $170.00 price objective on shares of Illumina in a research note on Wednesday, July 10th. TD Cowen upped their target price on Illumina from $166.00 to $177.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Canaccord Genuity Group raised their price target on shares of Illumina from $130.00 to $145.00 and gave the stock a "hold" rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $162.18.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.